GlaxoSmithKline Is Taking a Tough Approach to Budgets Post author:Sam Post published:March 20, 2018 Post category:BioPharma The head of GlaxoSmithKline’s pharmaceuticals division is pushing to cut its budget by 20 percent. Source: BioSpace You Might Also Like AstraZeneca Plots Crucial IDO Phase III Combo Trial With Incyte October 30, 2017 Celgene ReleaseData Presented At 2017 Further Evaluate Role Of ABRAXANE For Patients With Historically Challenging Cancers September 7, 2017 FDA Green Lights Gilead's Vosevi, With a Black Box Warning Attached July 18, 2017
Celgene ReleaseData Presented At 2017 Further Evaluate Role Of ABRAXANE For Patients With Historically Challenging Cancers September 7, 2017